The US Food and Drug Administration (FDA) has approved Pfizer and Myovant’s uterine fibroids drug Myfembree for the management of heavy menstrual bleeding.
MYOV and Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for the management of heavy menstrual bleeding